Analysts rate GeoVax Labs Inc. (GOVX:NSD) with a consensus Strong Buy rating and an average GOVX stock price target of $6.00 per share over the next 12 months.
Based on the GeoVax Labs Inc stock forecast from 1 analysts, the average analyst GOVX stock price target is USD 6.00 over the next 12 months. GeoVax Labs Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of GeoVax stock forecast is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, GeoVax stock price was USD 1.64. GeoVax stock price has changed by +0.46% over the past week, -1.09% over the past month and -65.83% over the last year.
About GeoVax Labs Inc. (GOVX:NSD):
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Most Recent Analyst Ratings for GeoVax’s Stock price:
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
|Initiated by||Maxim Group||
|Initiates Coverage On||Maxim Group||
What we like:
There is nothing we particularly like about the fundamentals om GeoVax’s stock.
What we don’t like:
Low market capitalization:
GeoVax stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The total returns for GeoVax stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow:
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth:
GOVX stock has shown below median earnings growth in the previous 5 years compared to its sector
Low Revenue Growth:
GOVX stock has shown below median revenue growth in the previous 5 years compared to its sector
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.